Results 21 to 30 of about 2,263,596 (244)
Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas
Hematology/Oncology and Stem Cell Therapy, 2023 Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy ...
Hamza Hashmi +2 more
doaj +1 more source
Antibody Drug Conjugates for Cancer Therapy
Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017 BACKGROUND AND OBJECTIVE: In recent decades, the use of antibody drugs conjugates (ADCs) generated promise for the treatment of cancer. In this type of treatment, a monoclonal antibody against a cancer specific antigen is used, and a cytotoxic drug is ...
S M Gheibi hayat, AH Sahebkar
doaj +1 more source
Pharmaceuticals, 2022 Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj +1 more source
Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold [PDF]
, 2022 Antibody-drug conjugates (ADCs) are a rapidly growing class of cancer therapeutics. The goal of ADCs is to overcome the low therapeutic index of conventional cytotoxic agents. However, realizing this goal has been a significant challenge.
Pradeep , Shrestha +4 more
core +2 more sources
A disruptive clickable antibody design for the generation of antibody-drug conjugates
, 2023 298310Background: Antibody-drug conjugates are cancer therapeutics that combine specificity and toxicity. A highly cytotoxic drug is covalently attached to an antibody that directs it to cancer cells. The conjugation of the drug-linker to the antibody is
Miriam-Kousso Assi +11 more
core +1 more source
Microbial Cell Factories, 2018 Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role in protein engineering among the high-throughput display methodologies that have been developed to date. The classical yeast display technology relies on tethering
Doreen Könning, Harald Kolmar
doaj +1 more source
Antibody–Drug Conjugates—A Tutorial Review
Molecules, 2021 Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small ...
Stephanie Baah +2 more
doaj +1 more source
Resistance to Antibody–Drug Conjugates [PDF]
Cancer Research, 2018 Abstract Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent.
García-Alonso, Sara +2 more
openaire +3 more sources
Emerging new therapeutic antibody derivatives for cancer treatment
Signal Transduction and Targeted Therapy, 2022 Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin +7 more
doaj +1 more source
Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation
Medicine in Drug Discovery, 2022 Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects of drugs have emerged a rapid development in recent years.
Weiran Cao +9 more
doaj +1 more source